Christopher Posner - 04 Apr 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (TVRD)

Reporting relationship: President and CEO, Director
Issuer ticker: TVRD
Reported as of: 04 Apr 2022
Net transaction value: -$25,416
SEC form: 4
Accepted by SEC: 05 Apr 2022, 17:48:17 UTC
Prior SEC filing: 01 Mar 2022
Next SEC filing: 18 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/Darren DeStefano, Attorney-in-Fact

Key filing fact

Christopher Posner filed Form 4 for Cara Therapeutics, Inc. (TVRD) on 05 Apr 2022.

Key facts

This page summarizes Christopher Posner's Form 4 filing for Cara Therapeutics, Inc. (TVRD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Apr 2022, 17:48.

Change

Previous filing in this sequence was filed on 01 Mar 2022.
Current net transaction value: -$25,416.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CARA transaction

Common Stock

Sale

Transaction value: $25,416
Shares: -2,006
Change %: -0.99%
Price: $12.67
Shares after: 201,031
Date: 04 Apr 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on May 28, 2021 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units reported in the Form 4 filed with the Securities and Exchange Commission on November 3, 2021, and does not represent a discretionary trade by the Reporting Person.